Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
+$1.50 today
- Market cap
- $10.34B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
Volume 0.68M
Average 0.58M
KYMR Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Kymera Therapeutics, Inc.NASDAQ: KYMR
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $18.94M rose 22.8% year over year, ahead of the +11.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 18.3% from the prior quarter. Over 3 fiscal years it compounded at +19.1% a year.
Context
- Stock-based compensation amounted to 152.8% of revenue in FY2025, up 35.9 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +22.8% holds above the trailing-twelve-month pace of +11.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 59.9M USD
- Year-over-year change
- +8.9%
- 4-year CAGR
- +24.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 59.9M | +8.9% |
| FY2024 | 2024-12-31 | 55.01M | +27.6% |
| FY2023 | 2023-12-31 | 43.12M | +21.5% |
| FY2022 | 2022-12-31 | 35.48M | +42.1% |
| FY2021 | 2021-12-31 | 24.97M | — |
Stock-Based Compensation vs competitors
How KYMR compares with its peers on the latest reported figures
- KYMR's LTM Jun 2026 stock-based compensation of $65.2M is the largest of the 5 companies compared; the peer median is $19.16M.
- Its year-over-year change of +11.7% is the highest of 5, against a peer median of -19.3%.
- Stock-based compensation amounts to 62.1% of revenue for KYMR, versus a peer median of 33.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.2M | +11.7% | +19.1% | 62.1% | |
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
| LTM Mar 2026 | $19.52M | +5.2% | +17.4% | 45.4% | |
| LTM Mar 2026 | $18.8M | -77.8% | -16.5% | 21.0% | |
| LTM Mar 2026 | $16.26M | -43.8% | -14.0% | 46.7% | |
| Peer median (excluding KYMR) | $19.16M | -19.3% | -1.7% | 33.2% | |
Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.35M) |
| Depreciation & Amortization | 2.4M | 2.98M | 3.57M | 7.37M | 8.31M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.97M | 35.48M | 43.12M | 55.01M | 59.9M |
| Change in Working Capital | (61.92M) | (37.62M) | 9.25M | (23.97M) | 15.27M |
| Accounts Receivables | 577K | (2.4M) | (16.23M) | 17.82M | 947K |
| Inventory | 8.71M | 2.4M | 0 | 0 | 0 |
| Accounts Payables | 54K | 253K | 0 | (307K) | (1.97M) |
| Other Working Capital | (71.26M) | (37.88M) | 25.48M | (41.48M) | 16.29M |
| Other Non-Cash Items | 5.83M | 889K | (11.8M) | (9.06M) | (5.02M) |
| Operating Cash Flow | (128.95M) | (153.09M) | (102.83M) | (194.5M) | (232.89M) |
| Capital Expenditures | (1.6M) | (2.84M) | (34.48M) | (12.84M) | (1.45M) |
| Acquisitions (Net) | 5.81M | (20.52M) | 0 | 0 | 0 |
| Purchases of Investments | (456.4M) | (445.97M) | 0 | (901.23M) | (1.01B) |
| Sales of Investments | 358.17M | 469.33M | 0 | 496M | 479.14M |
| Other Investing Activities | (5.81M) | 20.52M | 174.37M | 13.98M | 8.88M |
| Investing Cash Flow | (99.84M) | 20.52M | 139.89M | (404.08M) | (521.06M) |
| Debt Repayment | (849K) | (1.13M) | (76K) | (1.58M) | (1.49M) |
| Common Stock Issued | 243.11M | 149.83M | 0 | 596.62M | 992.21M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.02M | 4.3M | 4.27M | 13.81M | 0 |
| Financing Cash Flow | 250.28M | 153M | 4.19M | 608.85M | 990.71M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 21.5M | 20.43M | 41.25M | 10.27M | 236.76M |
| Free Cash Flow | (130.54M) | (155.92M) | (137.31M) | (207.34M) | (234.34M) |
Kymera Therapeutics, Inc.
NASDAQ:KYMR
Intrinsic Alpha fair value
Locked
Current Price
$121.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.